Heart Failure, Congestive Clinical Trial
Official title:
Health E Heart Study (South Texas Veterans Health Care System Heart Failure Disease Management Program/Study)
The primary objective of this telephonic heart failure specific patient education study is to assess the incremental clinical, psycho-social, and functional lifestyle benefits of the Health E Heart Study (South Texas Veterans Health Care System Heart Failure Disease Management Program/Study) when added to standard care among veteran beneficiaries with a heart failure diagnosis. A secondary objective is to assess the impact of the Health E Heart Study on total system utilization costs.
CHF is one of the most common diagnoses for Department of Veterans Affairs (VA) patients.
Cost of care, particularly inpatient hospitalization, is high dollar expenditure in the
budget.
Study subjects, recruited from the enrolled patient population of the STVHCS, are identified
by a diagnosis of CHF in VA clinical databases. Administrative and clinical inclusion and
exclusion criteria will be applied by review of medical records. Subjects who appear to meet
inclusion criteria will be mailed a pre-enrollment letter containing an Information Sheet
describing the program. A follow-up phone call by an RN will go over the program in detail,
review the Information Sheet, and initiate enrollment if the subject wishes to participate.
As a less than minimal risk study, verbal consent or refusal will be documented in the
respective subject's computerized medical record. Assenting subjects will be randomized by
the last digit of the social security (odd and even) in a 1:1 ratio to the control group
(standard care at STVHCS) or the intervention group (receiving the telephonic disease
management services in addition to standard care). The intervention group will receive a
telephonic intervention for one year that consists of formal scheduled nurse telephone
education sessions, 24-hour access to a nurse counseling and symptom advice telephone line,
printed action plans, workbooks, and individualized assessment letters, medication
compliance reminders, vaccination reminders, and physician alerts about signs and symptoms
of decompensation. Once enrolled, the RN conducts a telephonic assessment at intake, 6, and
12 months to assess each participant's knowledge, behavior, and health status related to the
HF condition.
All subjects enrolled in the study will continue to receive comprehensive heart failure care
from the STVHCS with those subjects randomized to the program receiving the additional
telephonic intervention. Risk stratification is determined from a combination of review of
the medical record patient admission history, and other self-reported information. Factors
considered include: Goldman Specific Activity Scale, self-management practices, medical
history, medical management, and psychosocial factors. The algorithm employs Boolean logic
and sorts patients into one of three categories that determines the frequency of scheduled
calls over the course of the year. The communications to physicians occurs through the VA
CPRS system regularly, usually after each scheduled patient call. Pre-specific clinical,
process, and economic outcomes will be collected on all subjects and analyzed at 6 and 12
months post-randomization.
Comparisons: The study will compare resources consumed in providing care to patients with
heart failure post-randomization receiving standard care with resources consumed with
standard care supplemented by the Health E Heart Disease Management Program. The study will
measure direct VA medical care costs.
Study subjects will all receive comprehensive medical care for congestive heart failure from
the STVHCS. Experimental subjects will receive additional telephone calls, patient education
sessions, customized treatment and self-management plans, and written patient education
materials. All subjects will receive telephonic assessments of health status, and functional
status at 6 and 12 months after randomization.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01357850 -
A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure
|
Phase 2 | |
Recruiting |
NCT00532688 -
N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure
|
Phase 2/Phase 3 | |
Terminated |
NCT00383630 -
Bone Marrow Cell Transplantation to Improve Heart Function in Individuals With End-Stage Heart Failure
|
Phase 2 | |
Completed |
NCT00531661 -
CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients
|
N/A | |
Completed |
NCT00149435 -
Cardiovascular Health Study (CHS) Events Follow-up Study
|
||
Completed |
NCT00159614 -
Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment
|
Phase 2 | |
Completed |
NCT00241761 -
Epidemiology of Depression and Heart Failure in Aging
|
N/A | |
Terminated |
NCT00125437 -
Larger Dose of Spironolactone for the Treatment of Patients With Nonischemic Cardiomyopathy
|
N/A | |
Completed |
NCT00202579 -
Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure
|
Phase 2 | |
Completed |
NCT00094263 -
Long-Term Predictors of Morbidity in Older Age
|
N/A | |
Terminated |
NCT00357591 -
Randomized Trial for Patients With Chronic Heart Failure With Acute Decompensation
|
N/A | |
Completed |
NCT00048425 -
Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.
|
Phase 3 | |
Completed |
NCT00023556 -
Genetic Architecture of Heart Disease in Rural Brazil
|
N/A | |
Completed |
NCT00530426 -
Heart Failure Registry
|
Phase 4 | |
Terminated |
NCT00190359 -
Growth Hormone and Heart Failure
|
N/A | |
Completed |
NCT00004562 -
Occluded Artery Trial (OAT)
|
Phase 3 | |
Completed |
NCT00005265 -
Natural History of Coronary Heart Disease
|
N/A | |
Completed |
NCT02772068 -
Hemodynamic Response to Exercise in HFpEF Patients After Upregulation of SERCA2a
|
Early Phase 1 | |
Completed |
NCT02925546 -
A Phase I Study to Assess the Pharmacokinetics of GSK2798745 Tablets
|
Phase 1 | |
Completed |
NCT01074307 -
A Prospective, Open-labeled, Multi-centric Trial in Subjects With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea
|
Phase 4 |